B+
Bull case
25%
Probability
Target price
$63.00
Analysis reference price unavailable
Analysis 2026-09-09 · RankAlpha Sentiment Codex
RIGL
RigelANasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
50%
Probability
Target price
$53.00
Analysis reference price unavailable
Analysis 2026-09-09 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$38.00
Analysis reference price unavailable
Analysis 2026-09-09 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-09-09
Recent news sentiment (30D)
+0.2
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
-
Unavailable
Sentiment proxy
+76.2
Score
AI commentary
Primary-source tone is mixed-positive, supported by profitability, updated revenue guidance, VEPPANU launch preparation, and R289 progress. Coverage is sparse, and unavailable analyst revisions, market-reaction attribution, social data, options data, short interest, and employee sentiment limit conviction; this remains a tentative monitoring view. [#SEC-8K-2026-08-04]
RankAlpha Sentiment Codex - 2026-09-09
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-12-08eventVEPPANU launch executionHigh impact
Rigel completed the exclusive global VEPPANU license, paid a $70 million upfront payment, and expected U.S. commercial availability in mid-August 2026. Early prescribing, reimbursement, channel execution, and contribution to guidance remain unverified and could drive the next material rerating. [#SEC-8K-2026-08-04]
2026-12-31catalystExecution against 2026 revenue outlookHigh impact
Rigel reported Q2 2026 revenue of $78.7 million, net product sales of $67.0 million, and net income of $17.3 million, while maintaining an updated 2026 revenue outlook of approximately $285-$295 million. Delivery against that outlook is the key near-term validation point. [#SEC-8K-2026-08-04]
2026-12-31catalystR289 lower-risk MDS development milestonesHigh impact
The Phase 1b dose-expansion study remains on track to complete enrollment, select a recommended Phase 2 dose in the second half of 2026, and provide preliminary data by year-end. This is meaningful pipeline optionality but remains early-stage and clinically risky. [#SEC-8K-2026-08-04]
Recommendation
N/A
No formal recommendation provided.
As of 2026-09-09 • Updated nightlySource: Internal modelMethodology